# US 2026/0241028 A1 · Metal-based antibody-drug conjugates and methods of making and using thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0241028 A1
- Document ID: US20260241028A1
- Status: Published application
- Kind: A1
- Application number: 19/170,569
- Filed: 2025-04-04
- Published: 2026-08-20
- Earliest claimed: 2024-04-19
- Applicants: Laboratory for Synthetic Chemistry and Chemical Biology Limited
- Inventors: Chi-Ming Che; Chun Ho Chu
- Web page: https://patentgrep.com/patent/US20260241028A1

## CPC

- A61K 47/6801: {Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent}
- A61K 47/6887: {Antibody-chelate conjugates using chelates for therapeutic purposes (radioactive substances, e.g. for use in radio diagnosis or radiotherapy, A61K51/10; antibody-chelates for use in MRI A61K49/14)}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Metal-based antibody-drug conjugates are described herein. Methods of making and using thereof are also described. The conjugates, and pharmaceutical compositions thereof, can be used in anticancer therapies.

## Claims

### Claim 1

A metal-based antibody-drug conjugate comprising:
a gold (III) porphyrin;
a linker group; and
an antibody;
wherein the linker group covalently links the gold (III) porphyrin and the antibody.

### Claim 2 (depends on 1)

The conjugate of claim 1, wherein the metal-based antibody-drug conjugate has a chemical structure according to Formula (I):
wherein L is the linker group;
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of a hydrogen; halogen group; a C2-C5 alkyl group; alkenyl group; alkynyl group; cycloalkyl group; cycloalkenyl group; cycloalkynyl group; a hydroxyl group; an alkoxy group, such as methoxy, ethoxy, propoxy, or butoxy; an aryl group; a heteroaryl group; a benzyl group; an acyl group; an ester group; a carbonyl group; a carboxylate group; an amino group; an amide group; and a nitro group;
wherein R5, R6, and R7 are optional substituents and are each independently selected from the group consisting of a halogen group; a C2-C5 alkyl group; alkenyl group; alkynyl group; cycloalkyl group; cycloalkenyl group; cycloalkynyl group; a hydroxyl group; an alkoxy group; an aryl group; a heteroaryl group; a benzyl group; an acyl group; an ester group; a carbonyl group; a carboxylate group; an amino group; an amide group; and a nitro group; and x, y, and z are integer values independently selected from 0-5;
wherein X− is a pharmaceutically acceptable counterion; and
wherein q is a value in a range of about 1 to 8.

### Claim 3 (depends on 2)

The conjugate of claim 2, wherein R1, R2, R3, and R4 are each hydrogen and/or x, y, and z are each 0.

### Claim 4 (depends on 2)

The conjugate of claim 2, wherein the linker group comprises an end-group, known as antibody-attachment moiety, such as a thiol-reactive Michael acceptor group or amine-reactive N-Hydroxysuccinimide, and/or the linker group comprises a spacer, and/or the linker group comprises one or more polyethylene (PEG) groups, and/or the linker group comprises a cleavable bond.

### Claim 5 (depends on 4)

The conjugate of claim 4, wherein the acid cleavable bond is a carbonate bond and the cathepsin B cleavable peptide is GGFG.

### Claim 6 (depends on 2)

The conjugate of claim 2, wherein the linker L has a chemical structure according to a structure of Formula (II) shown below:
wherein m is an integer value in a range from 4 to 10.

### Claim 7 (depends on 2)

The conjugate of claim 2, wherein the antibody is a monoclonal antibody; optionally wherein the monoclonal antibody is a TROP2-targeting, EGFR-targeting, or HER2-targeting monoclonal antibody.

### Claim 8 (depends on 7)

The conjugate of claim 7, wherein the TROP2-targeting monoclonal antibody is Sacituzumab, the EGFR-targeting monoclonal antibody is Cetuximab, or the HER2-targeting monoclonal antibody is Trastuzumab.

### Claim 9 (depends on 2)

The conjugate of claim 2, wherein the metal-based antibody-drug conjugate has one of the following structures:
wherein n has a value of about 1 to 8 or is about 4 or 8.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising:
a plurality of the metal-based antibody-drug conjugate of claim 1;
one or more pharmaceutically acceptable carriers; and
optionally one or more pharmaceutically acceptable excipients.

### Claim 11 (depends on 10)

A method of targeted cancer therapy, the method comprising the steps of:
(i) administering the pharmaceutical composition of claim 10 to a subject in need thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the subject has a cancer wherein the cancer cells thereof overexpress TROP2, EGFR, or HER2 receptor.

### Claim 13 (depends on 11)

The method of claim 11, wherein the cancer is selected from the group consisting of breast, lung, liver, kidney, colorectal, gastric, ovarian, and pancreatic cancer.

### Claim 14 (depends on 11)

The method of claim 11, where the plurality of the metal-based antibody-drug conjugate in the pharmaceutical composition provide a cytotoxicity against the TROP2, HER2, or EGFR-overexpressed cancer cells with an IC50 value ranging from about 2 to 170 nM.

### Claim 15

A method of making a metal-based antibody-drug conjugate comprising the steps of:
(a) forming or providing a gold (III) porphyrin comprising a linker group;
wherein the linker group comprises an end-group, known as antibody-attachment moiety, such as a thiol-reactive Michael acceptor group or amine-reactive N-Hydroxysuccinimide, and/or the linker group comprises a spacer, and/or the linker group comprises a cleavable bond; and
(b) conjugating the gold (III) porphyrin to a monoclonal antibody to form the metal-based antibody-drug conjugate;
wherein the monoclonal antibody comprises one or more thiol groups and at least one of the thiol groups undergoes a Michael addition with the Michael acceptor group of the linker group; or the monoclonal antibody comprises one or more amino groups and at least one of the amino groups undergoes a condensation reaction with the N-hydroxysuccinimide of the linker group.

### Claim 16 (depends on 15)

The method of claim 15, wherein the gold (III) porphyrin has a structure according to Formula (III):
wherein L is the linker group;
wherein MA is the Michael acceptor group;
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of a hydrogen; halogen group; a C2-C5 alkyl group; alkynyl group; cycloalkyl group; cycloalkenyl group; cycloalkynyl group; a hydroxyl group; an alkoxy group, such as methoxy, ethoxy, propoxy, or butoxy; an aryl group; a heteroaryl group; a benzyl group; an acyl group; an ester group; a carbonyl group; a carboxylate group; an amino group; an amide group; and a nitro group;
wherein R5, R6, and R7 are optional substituents and are each independently selected from the group consisting of a halogen group; a C2-C5 alkyl group; alkynyl group; cycloalkyl group; cycloalkenyl group; cycloalkynyl group; a hydroxyl group; an alkoxy group; an aryl group; a heteroaryl group; a benzyl group; an acyl group; an ester group; a carbonyl group; a carboxylate group; an amino group; an amide group; and a nitro group; and x, y, and z are integer values independently selected from 0-5;
and
wherein X− is a pharmaceutically acceptable counterion.

### Claim 17 (depends on 16)

The method of claim 16, wherein the linker L has a chemical structure according to one of the following structures of Formula (IV):
wherein m is an integer value in a range from 4 to 10.

### Claim 18 (depends on 15)

The method of claim 15, wherein the monoclonal antibody targets tumor-associated receptors, such as TROP2, HER2, Nectin4, folate receptor alpha, or EGFR.

### Claim 19 (depends on 18)

The method of claim 18, wherein the monoclonal antibody is a TROP2-targeting Sacituzumab, EGFR-targeting Cetuximab, or HER2-targeting Trastuzumab.

### Claim 20 (depends on 15)

The method of claim 15, wherein the metal-based antibody-drug conjugate has one of the following structures:
wherein n has a value of about 1 to 8 or is about 4 or 8.
